Title: Treatment of Cancer by Inhibiting BRAF Expression. Number: 20050019918. Filed: April 29, 2004. Lead Inventor: Hidetoshi Sumimoto, Keio University School of Medicine.
“The … invention relates to a therapeutic method using RNAi directed at BRAF, of which the point mutation, especially V599E, occurs frequently in melanomas,” the patent application’s abstract states. “RNAi specific for the mutated BRAF will provide a specific therapeutic intervention for cancers such as malignant melanoma.